Poly MVA | Alternative Cancer Treatment

Cancer Patient Testimonials

Poly MVA Survivors
Testimonials Written by Cancer Patients
.


HOME	TESTIMONIALS	POLY-MVA RESEARCH	WHAT YOU MUST KNOW

Scientific Research


KGK Synergize Independent Lab Tests on 8 Cancer Cell Lines	Oncology Study Board Certified Oncologist 1,000 Patient/Stage IV Study	Published Articles Poly-MVA/Palladium-α-Lipoic Acid articles on Pubmed.com	Poly MVA Inventor See List of Patent filings for Dr. Merrill Garnett

In 2007, KGK Synergize Inc., an independent laboratory in Canada, examined the effects of POLY-MVA on 8 cancer cell lines.

These lines included:
1) Skin melanoma, human (SKMel-5)
2) Liver, hepatocellular carcinoma, human (Hep G2)
3) Lung, malignant melanoma, human (Malme-3M)
4) Mammary gland, ductal carcinoma, human (MDA-MB 435)
5) Prostate, left supraclavicular lymph node carcinoma, human (LNCaP)
6) Colon, colorectal adenocarcinoma, human (HT-29)
7) Human brain, glioblastoma; astrocytoma (U87)
8) Glioblastoma (HT-80)

POLY-MVA was administered at 3 different dosages and the number of cells was examined after 24, 48 and 72 hours following initial application. POLY-MVA was effective, to varying degrees, on the entire group of cell lines tested (melanoma, liver, lung, breast, prostate, colon, astrocytoma and glioblastoma).
.
The varying effectiveness appears to be a consequence of the particular cell lines used and their associated degree of anaplasia.

The graph below demonstrates the benefit of POLY-MVA after 48 hours of initial exposure:
The Y-axis represents the number of cells per mL.

Poly MVA causes significant cell death after 48 Hours of exposure
per mL. SHAPE \* MERGEFORMAT CPM
The table below illustrates the statistically significant level of cell death
(p must be equal to or less than 0.05) induced by POLY-MVA after 48 hours of initial exposure:

Cancer Cell Type		Cell Line	Statistical Significance	Dosages (ug/ml)
Melanoma	SKMel-5		p<0.01	100, 1000
Liver	Hep G2		p<0.01	1000
Lung	Malme-3M		p<0.0004	100, 1000
Breast	MDA-MB 435		p<0.001	1000
Prostate	LNCaP		p<0.0005	1000
Colon	HT-29		p<0.03	10, 100, 1000
Astrocytoma	U-87		p<0.05; p<0.01	10, 100; 1000
Glioblastoma	HT-80		p<0.0001	10, 100, 1000

Garnett McKeen In vitro Cancer Assays:
Garnett McKeen Laboratory Inc. (GML) chose to mimic the National Cancer Institute’s (NCI) cell screening protocol.

The following cell lines were selected from the NCI repository:

MCF-7 (breast adenocarcinoma), and A549 (lung non-small cell adenocarcinoma).

The data below represents the completion of the Breast Cancer (MCF-7), Ovarian Cancer (OVCAR-5) and Lung Carcinoma (A549) assay.

We have also completed assays using stage IV glioblastoma multiforme (H-80) and astrocytoma (H-4) brain tumor lines.

As noted below, all of the studies demonstrated significant cell death.

CANCER CELL DEATH RATE IN 5 CELL LINES
After 48 hours of exposure

Breast Cancer

(Adenocarcinoma)

91.1%

Breast Cancer Cell Death after 48 Hours

Ovarian Cancer

(Adenocarcinoma)

92.07%

Ovarian Cancer Cell Death after 48 Hours

Lung Cancer

(Non-Small Cell Carcinoma)

83.8% Percentage

Lung Cancer Cell Death after 48 Hours

Brain Tumor (Glioblastoma) 96.3% Percentage Brain Cancer Cell Death after 48 Hours	Brain Tumor (Astrocytoma) 82.5% Percentage Brain Cancer Cell Death after 48 Hours

For Doctors and Patients
.

Oncologist touts the benefits of Poly-MVA(LAMC)

James Forsythe, MD, HMD

Century Wellness Clinic in Reno, NV

"The long-term positive impact I have seen in our clinic is quite astounding. Since 2004, we've performed 3 outcome studies in over 1700 patients with Poly-MVA(LAMC).

Poly-MVA provides a significant difference as a stand-alone or Integrative Protocol and also continues to show outstanding impact for each patient's success & overall health."

Stage IV Study - 1,000 Patients
.